Clinical trials: Immunoglobulin G4 Related Sclerosing Disease, active
IgG4 Related Disease, Systemic Sclerosis (SSc)
Nebulized UC-EVs for Recurrent or Refractory IMIDs With Lung Involvement
Immune-mediated inflammatory diseases (IMIDs) are systemic inflammatory disorders driven by dysregulated immune responses that can affect multiple organs, including the lungs.
- Trial name
- NCT07806045
- Testing
- nebulized human umbilical cord mesenchymal stromal cell-derived extracellular vesicles
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Qiubai Li
IgG4-related Disease
Study of Sirolimus in IgG4-related Disease
gG4-related disease (IgG4-RD) is a newly recognized systemic autoimmune disease that can involve the pan-creatobiliary tract, retroperitoneum/aorta, head and neck region, and salivary glands, et al.
- Trial name
- NCT05746689
- Testing
- Sirolimus
- Volunteers
- 20 people
- Sponsor
- Peking University International Hospital
IgG4-related Disease
A Prospective Cohort Study of IgG4RD in China
This is an cohort study to investigate the disease course and treatment response of patients with IgG4-related disease.
- Trial name
- NCT01670695
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Peking Union Medical College Hospital
Autoimmune Diseases, Lupus Erythematosus, Systemic
Comparative Autoantibody and Immunologic Cell Marker Study
The purpose of this study is to compare immune phenotype, function, and specificity of B lymphocytes from different developmental stages in autoimmune patients to B cells from infectious disease patients and healthy controls.
- Conditions
- Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases
- Trial name
- NCT02422875
- Where
- 3 sites in United States
- Volunteers
- 2,500 people, healthy volunteers welcome
- Sponsor
- Emory University
IgG4 Related Disease
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
- Trial name
- NCT07061938
- Testing
- ACE1831, Lymphodepleting chemotherapy
- Where
- 11 sites in United States, China and 1 more
- Volunteers
- 34 people
- Sponsor
- Acepodia Biotech, Inc.
IgG4 Related Disease
Adaptive and Trained Immunity in the Pathogenesis of IgG4-Related Disease
Enquire involvement of trained immunity in the pathogenesis of IgG4RD
- Trial name
- TRIM4 (NCT06844864)
- Where
- Italy
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
IgG4 Related Disease
An Exploratory Clinical Study on the Safety and Efficacy of CD19/BCMA CAR-NK in the Treatment of Relapsed and Refractory IgG4-related Disease
A single arm, open-label pilot study is designed to determine the safety and effectiveness of CD19/BCMA CAR NK cells (KN5601) in patients with IgG4 related diseases.
- Trial name
- NCT07298590
- Testing
- CD19/BCMA CAR NK
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Changhai Hospital
Fever of Unknown Origin, IgG4 Related Disease
The Investigators Will Evaluate the Diagnostic Performance of [18F]-AlF-FAPI-74 PET/CT in Inflammatory Disorders and Compare it With the Current Gold Standard for Inflammation, FDG PET/CT, in Three Patient Cohort: Patients Presenting With Fever of Unknown Origin, IgG4-RD and AxSpA.
The aim of the study to evaluate the performance of new [18F]-AlF-FAPI-74 PET/CT in three inflammatory disorders (fever of unknown origin, IgG4-related disease and axial spondyloarthritis) and compare with the current…
- Conditions
- Fever of Unknown Origin, IgG4 Related Disease, Axial Spondylarthritis (axSpA), Inflammation of Unknown Origin
- Trial name
- NCT07535554
- Testing
- [18F]AlF-FAPI-74 PET/CT
- Where
- Belgium
- Volunteers
- 140 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
IgG4 Related Disease
A Randomized Controlled Study of the Efficacy and Safety of Lenalidomide in the Treatment of Active IgG4-related Disease
For patients with active proliferative IgG4-RD, we plan to conduct a 52-week prospective randomized controlled trial to compare the efficacy and safety of 5mg lenalidomide plus prednisone, 10mg lenalidomide plus prednisone, and…
- Trial name
- IgG4-RD (NCT07068165)
- Testing
- 5mg lenalidomide, 10mg lenalidomide, Prednisone monotherapy
- Where
- China
- Volunteers
- 198 people
- Sponsor
- Peking Union Medical College Hospital
IgG4 Related Disease
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).
- Trial name
- NCT04540497
- Testing
- Inebilizumab
- Where
- 72 sites in United States, Argentina and 19 more
- Volunteers
- 135 people
- Sponsor
- Amgen
IgG4-Related Disease
National Registry of IgG4-RD in China
The aim of this study is to establish a nation-wide cohort study of IgG4-related disease (IgG4-RD) in China. Methods: All the patients fulfilling diagnostic criteria of IgG4-RD (2011) would be enrolled from multi-centers around…
- Trial name
- NCT03023371
- Where
- China
- Volunteers
- 900 people
- Sponsor
- Peking Union Medical College Hospital
Behcet's Disease, Idiopathic Inflammatory Myopathies
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Research into novel therapies for rare, immune-mediated inflammatory diseases (IMIDs) is limited due to small patient populations.
- Conditions
- Behcet's Disease, Idiopathic Inflammatory Myopathies, IgG4-related Disease
- Trial name
- DRIMID (NCT06285539)
- Testing
- Filgotinib
- Where
- 6 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- UMC Utrecht
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497387
- Testing
- PRG-1801
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tongji Hospital
Immunoglobulin G4-Related Disease
Efficacy and Safety of Lenalidomide in Patients With IgG4-Related Disease
Immunoglobulin G4-related disease (IgG4-RD) is a chronic immune-mediated disorder characterized by inflammation, fibrosis, and involvement of multiple organs.
- Trial name
- LENITY (NCT07719543)
- Testing
- Lenalidomide
- Where
- 3 sites in China
- Volunteers
- 146 people
- Sponsor
- Chinese PLA General Hospital
Immunoglobulin G4-Related Disease
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target
This is a monocentric, comparative, cross-sectional, case-control study seeking to identify abnormalities of the C5a-C5aR1 axis between a population of patients with active IgG4-associated disease (MAG4) and two control groups…
- Trial name
- C5-MAG4 (NCT06270524)
- Testing
- Blood sampling
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
IgG4 Related Disease, B-cell Mediated Autoimmune Disorders
Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease
The goal of this clinical trial is to test the safety and potential benefit of a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults (18-75 years) with IgG4-related disease (IgG4-RD) that has come back or not…
- Trial name
- BC19IGG4 (NCT07148791)
- Testing
- Anti-BCMA-CD19 CAR-T cells
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese PLA General Hospital
Immunoglobulin G4 Related Disease
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.
- Trial name
- RILIEF (NCT07190196)
- Testing
- Rilzabrutinib, Glucocorticoid
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Immunoglobulin G4-related Disease
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
The primary objectives of this study are to characterize the pharmacokinetics (PK) and pharmacodynamics (PD), as well as to assess the safety and tolerability, of inebilizumab in pediatric participants with IgG4-RD.
- Trial name
- NCT07222553
- Testing
- Inebilizumab
- Where
- 14 sites in United States, Brazil and 5 more
- Volunteers
- 15 people
- Sponsor
- Amgen
IgG4-related Disease
BCT301 in Treating Refractory/Recurrent IgG4-related Disease
This is an investigator initiated trial to assess the safety and efficacy of BCT301 cell Injection (CAR-iT cells derived from chemically induced pluripotent stem cells) in patients with refractory/recurrent IgG4-related disease.
- Trial name
- NCT07793903
- Testing
- BCT301 Cell Injection
- Volunteers
- 6 people
- Sponsor
- Peking University Third Hospital
Lupus Nephritis, IgG4-related Disease
Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
A Clinical Study on the Safety and Effectiveness of CD19/BCMA Chimeric Antigen Receptor T Cells in the Treatment of Refractory Lupus Nephritis and IgG4-Related Disease.
- Trial name
- NCT06497361
- Testing
- PRG-2311
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital